BERGENBIO ASA: INVITATION TO PRESENTATION OF SECOND QUARTER AND HALF YEAR 2021 RESULTS
Bergen, Norway, 4 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the second quarter and half year 2021 on Tuesday 17 August 2021. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET. The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished. The second quarter report and